Prospector
Profile
1020-02
|
| |
| Psivida Limited |
NAICS |
339115 |
| Level 12 BGC Centre 28, The Esplanade
Perth, Australia 6000 |
Description |
Opthalmic Products Mfg. |
| +61-8-92265099 |
Employees |
0 |
| http://www.psivida.com/ |
Revenue |
AUD(mil) |
2.2820 |
| |
Income |
AUD(mil) |
-122.2580 |
| |
Assets |
AUD(mil) |
101.5540 |
| |
Liability |
AUD(mil) |
23.8340 |
| |
(for the year ended 2007-06-30) |
| |
|
Category:
Audit Concerns
|
| |
|
Event:
Deloitte Touche Tohmatsu expressed doubts on the ability of Psivida Limited to continue as a going concern after auditing its financial statements. The auditor points to the Company’s recurring losses from operations and negative cash flows from operations.
|
| |
|
Intellectual Property:
As of August 31, 2007, the Company had 105 patents and 310 pending patent applications, including patents and pending applications covering its Durasert, BioSilicon and Codrug technologies. The Company expects to aggressively try to patent and protect proprietary technologies. It also relies on trade secrets, know-how and technology that are not protected by patents to maintain competitive position. [SEC Filing 20-F 10-01-07]
|
| |
|
Description:
The Company is engaged in the development and commercialization of drug delivery products in the healthcare sector, initially in ophthalmology and oncology.
|
| |
|
Officers:
Paul Ashton (Managing Dir.); Aaron Finlay (Sec.); Lori Freedman (VP, Gen. Counsel & Sec.); Michael Soja (VP, CFO & Treas.)
|
| |
|
Auditor:
Deloitte Touche Tohmatsu
|
| |
|
Securities:
Common Stock-Symbol PSDV; Nasdaq;
565,950,830 common shares outstanding as of June 30, 2007.
|
| |
| |
| |
| return to main page |
